Image Credit: Super Vision
Super Vision was founded in Beijing in 2018 by professors from the Peking University and Beijing University of Technology. It developed the i-NYS implantable stimulation device for the treatment of congenital nystagmus – a condition where the eyes move rapidly and uncontrollably.
Congenital nystagmus is commonly starts in infants between between 6 weeks and 3 months old. Children with this condition tend to have it in both eyes, which move side to side. Children with nystagmus typically experience blurry vision. It affects some 10 million people worldwide.
Congenital nystagmus has traditionally been considered incurable. However, Super Vision developed an implantable device to stimulate the extraocular rectus muscle with the intention of inhibiting abnormal activation, therefore treating nystagmus.
In 2023 Super Vision completed 71 clinical implants in 45 adult and 26 pediatric patients. They have submitted their application for approval from NMPA.
Image Credit: Super Vision
Thanks to Victor Pikov for making me aware of this company!